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Abstract: Hepatoblastoma is the most common hepatic malignancy during childhood. However,
little is still known about the molecular mechanisms that govern the development of this disease.
This review is focused on the recent advances regarding the study of microRNAs in hepatoblastoma
and their substantial contribution to improv our knowledge of the pathogenesis of this disease.
We show here that miRNAs represent valuable tools to identify signaling pathways involved in
hepatoblastoma progression as well as useful biomarkers and novel molecular targets to develop
alternative therapeutic strategies in this disease.
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1. Introduction
Hepatoblastoma (HB) is a pediatric tumor that arises from hepatic progenitors or hepatoblasts.
It is the most common malignancy of the liver occurring in the pediatric population, with an annual
incidence rate of 1.5 cases per million that represents around 1% of total cancers in childhood [1].
However, its incidence has increased by 2.7% per year over the last decades, probably due to the
improved survival of premature infants [2]. Disease stage is the current key determinant of patient
outcome, and the subgroup of cases with lower risk has a 5-year event-free survival rate of 80%
that decreases to 30–40% in the subgroup of high risk or after relapse [3]. Progressive advances in
surgical techniques and chemotherapy regimens have resulted in higher survival rates in cases with
localized disease, but in that 25% of cases who develop metastases, the prognosis remains very poor [4].
Although the Wnt/β-catenin, Myc, and Hippo pathways have been reported to be involved in the
pathogenesis of HB tumors, little is still known about the molecular basis of this disease. In fact,
deletions and missense mutations affecting β-catenin protein that cannot be degraded have been
found in more than 80% of HB cases, further highlighting the role of this pathway in the disease
development [5–7]. Moreover, deregulation of the Hippo pathway promotes proliferation, migration
and apoptosis resistance, and there has been reported interesting crosstalk between Hippo signaling
and microRNAs (miRNAs) in cancer progression that could be of high relevance in HB tumors [8].
Therefore, it is urgent to identify novel targets and signaling pathways altered in this disease in order
to develop more effective therapeutic strategies to improve HB patient outcomes.
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MiRNAs are a class of small (19–25 nucleotides) single-stranded and non-coding RNAs that serve
as major regulators of gene expression through their ability to bind and post-transcriptionally inhibit
the expression of specific target messenger RNAs [9]. The microRNA biogenesis and functional role are
schematized in Figure 1. In the nucleus, miRNA genes are transcribed by RNA polymerase II (or less
frequently polymerase III) to form pri-miRNAs, which include hundreds of nucleotides and a terminal
loop structure with flanking segments. Next, Drosha RNase III endonuclease cuts the pri-miRNA to
liberate a pre-miRNA hairpin (a 60–70 nucleotide long hairpin RNA with 2 nucleotides overhangs
at its 3′-end). The pre-miRNA is then transported by exportin-5 from the nucleus to the cytoplasm.
The pre-miRNA duplex contains the mature miRNA guide and its complementary passenger strand
(miRNA *, *: complementary passenger strand). Considering the widely accepted model, miRNA * is
degraded, although evidence suggests that miRNA * may also be functional as well. In the cytoplasm,
the pre-miRNA is cleaved by Dicer RNase III endonuclease into a single-strand mature miRNA that
binds to proteins of the Argonaute (Ago) family, assembling the RNA-induced silencing complex
(RISC). Finally, the “seed region” (a 5′-end region of the mature miRNA, which includes 2–8 nt) binds
the 3′-UTR of the target mRNA (Figure 1). According to the match level, the target mRNA will be
degraded or blocked, and its translation inhibited, but without decreasing its expression levels. In fact,
the complementarity in most animal miRNAs is imperfect, which results in translation inhibition [10].
Of note, each miRNA is able to regulate up hundreds of target genes, affecting the activity of entire
signaling pathways. On the contrary, a specific gene is often regulated by a high number of different
miRNAs and can have up to 50 miRNA binding sites [11]. Thus, miRNAs are predicted to regulate
approximately 60% of the human genes [12].
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Figure 1. MicroRNA biogenesis in mammalian cells. MiRNA genes are transcribed by RNA polymerase
to form the immature pri-miRNA, which is cut by Drosha to liberate a pre-miR which is transported by
Exportin-5 from the nucleus to the cytoplasm. The pre-miR is then cleaved by Dicer and the mature
miR binds to the RNA-induced silencing complex (RISC) and targets a specific mRNA.
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Of importance, miRNAs play a key role in regulating processes like proliferation, differentiation,
apoptosis, invasion, angiogenesis, and metastasis via gene expression manipulation [9]. In 2002, the
first report about the role of miRNAs in cancer established that the gene cluster containing the miRNAs
miR-15 and miR-16 is deleted in most people with chronic lymphocytic leukemia [13]. Further studies
have shown that miR-15 and miR-16 act as tumor suppressors by targeting the BCL2 oncogene, which
is involved in cell survival [14]. The importance of miRNAs in human cancer and their potential
clinical impact have been progressively growing. In fact, in 2014 the first phase-I clinical trial that used
miRNAs as a tool for cancer therapeutics started [15].
MiRNAs expression is frequently deregulated in many tumors and their specific target genes
determine whether they act as tumor suppressors or oncogenes in human cancers [9]. Thus,
the upregulation of oncogenic miRNAs reduces expression of tumor-suppressor proteins, but
downregulation of tumor suppressor miRNAs results in increased levels of oncogenic proteins.
Modulation of miRNA expression is thought to be an important mechanism by which tumor suppressor
proteins and oncoproteins exert some of their effects. Thus, the c-MYC oncoprotein induces the
expression of the miR-17-92 cluster [16] and also represses the transcription of many miRNAs with
tumor suppressor roles, such as the let-7 family [17]. In concordance, reduced expression of let-7
miRNAs has been reported in many cancers and correlates with poor outcomes [9]. The let-7 family
targets RAS proto-oncogene, GTPase (RAS), which is involved in the regulation of essential processes
such as cell growth, differentiation, or survival [18]. Moreover, the tumor suppressor p53 induces
the expression of the miR-34 family in response to DNA damage and loss of miR-34a expression
is associated with metastasis and recurrence of prostate cancer [19], and miR-34b and miR-34c
expression is lost through different molecular mechanisms including deletion, hypermethylation,
or downregulation in 90% of colorectal cancers [20]. Furthermore, negative regulation of specific
targets genes is not the only method by which miRs are implicated in human cancer. Mutations
affecting miRs binding sites in the 3’untranslated region (UTR) of oncogenes are correlated with an
increased risk of cancer. For instance, a single nucleotide polymorphism in the 3′UTR of the KRAS
oncogene has been found to significantly increase the risk of non-small-cell lung cancer [21]. Some
miRs are also involved in stemness regulation such as miR-296, miR-134, miR-470, and the miR-34
family, which targets genes essential for pluripotency as Oct4, NANOG, SOX2, NOTCH, and BCL2 [22].
Finally, miRs are important for regulating angiogenesis. The activation of proliferation and migration
pathways in vascular smooth muscle cells are key steps to promote angiogenesis by tumor cells. Thus,
in nasopharyngeal carcinoma cells, the miR-15a/16-1 cluster controls angiogenesis by targeting the
angiogenic factors VEGFA and MET [23].
2. MicroRNAs as Regulators of Signaling Pathways in Hepatoblastoma Cells
The oncogenic effects derived from the activation of both Myc and Wnt pathways, alterations
which have been described to play key roles in HB pathogenesis, are mediated at least in part by miRs.
Thus, undifferentiated aggressive HB showed the expression of miR-100/let-7a-2/miR-125b-1 and
miR-371-3 clusters downregulated and overexpressed respectively. Both clusters were found to be
regulated by Myc in an opposite manner and contributed to generate an HB aggressive phenotype
regulating proliferation and tumorigenicity in vivo [24]. Moreover, miR-4510 functions as a tumor
suppressor since it directly targets the glypican-3 (GPC3) oncogene and impairs the Wnt/β-catenin
pathway. In fact, miR-4510 inhibits the transcriptional activity of β-catenin without affecting its
expression, decreasing HuH6 cell viability [25]. Moreover, let-7i-3p, miR-449-3p, miR-624-5p and
miR-885-5p have also been identified as regulators of β-catenin that inhibit Wnt signaling in HB [26]
(Figure 2).
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However, several works exploring the role of miRs in HB have progressively provided additional
pathways altered in this disease. In vitro studies using the HB cell line HepG2 has shown that the
ATP-binding cassette transporter A1 (ABCA1) is a target of miR-101, and that this miR is overexpressed
by IL-6 and TNF-α, thereby inhibiting cholesterol efflux. Thus, high levels of miR-101 result in
cholesterol retention under inflammatory conditions [27]. More recently, other studies using the
same cell line HepG2 identified the efflux transporter ABCG2 as a direct target of miR-655-3p [28],
and miR-206 was found involved in the regulation of lipid metabolism [29]. Of note, miR-206 has
been reported to mediate YAP1 function, which could be of high relevance in HB [30]. In addition,
the GATA4/miR-125b/DKK3 signaling axis has emerged as a major regulator of cell proliferation,
migration, and invasion. The transcription factor GATA4 plays an oncogenic role through its binding
to the miR-125 promoter which inhibits its transcription, thereby impairing the suppression of
the miR-125b target DKK3 [31]. Moreover, the miR-492, described as overexpressed in metastatic
HBs [32], has been recently reported to play an oncogenic function in HB enhancing proliferation,
anchorage-independent growth, migration, and invasion, further straightening its previously proposed
role in HB progression. Moreover, CD44 was identified as a direct target of miR-492 also involved in
metastatic progression [33]. Considering the previously described tumor suppressor role of miR-124
in both cholangiocarcinoma [34] and HCC cells [35], Wang and colleagues performed a systematic
analysis to determine the potential role of this miR and its molecular mechanism in HB. HepG2
cells were transfected with a miR-124 precursor and differentially-expressed genes were screened at
different times by microarray analyses. A miR-124-target mRNA network and pathway enrichment
analyses were carried out, observing significant changes in small GTPase-mediated and Ras protein
signal transduction together with regulation of actin cytoskeleton, D-glutamine and D-glutamate
and axon guidance pathways [36]. Furthermore, it has been demonstrated that the tumor suppressor
miR-26a-5p directly targets LIN28B and AURKA in HB cells, which highlights the relevance of the
LIN28B-RAN-AURKA axis in the pathogenesis of this disease and the role of miR-26a-5p as a repressor
of this signaling [37].
Finally, the role of long non-coding RNAs (lncRNAs) in HB has been explored in several studies.
It has been reported that a signaling network involving miR-34a-5p, the lncRNA TUG1 and VEGF
plays a relevant role in angiogenesis and HB progression, and in which lncRNA-TUG1 functions as a
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miR-34a sponge regulating the expression of its target VEGF [38]. Recently, the lncRNA NEAT1 has
also been described as a relevant mediator of HB pathogenesis. This lncRNA exerts its function by
inhibiting miR-129-5p, which promotes migration and invasion as well as epithelial to mesenchymal
transition by modulating E-cadherin and N-cadherin levels [39]. Moreover, the lncRNA OIP5-AS1
inhibits miR-186a-5p-mediated suppression of ZEB1, which promotes the proliferation and EMT of
HB cells [40]. Of relevance, miR-186 has been reported to target YAP1, thereby inhibiting the Hippo
pathway in HCC, which could have important implications also in HB tumors [41], since YAP1 has
been reported to play a relevant role in the pathogenesis of this disease [42–44].
3. MicroRNAs as Potential Therapeutic Targets
The recent advances in our knowledge about the relevant role that miRs play in HB have
highlighted their potential efficacy as novel molecular targets in this disease (Table 1). Thus, an
in vivo cooperation between the miR-100/let-7a-2/miR-125b-1 and miR-371-3 clusters in HB has
been demonstrated, and the overexpression of the first cluster delayed tumor occurrence, whereas the
simultaneous inhibition of the miR-371 cluster totally blocked tumor formation [24]. Moreover, miR-122
has been proposed as a potential target in HB based on its ability to sensitize cells to 5-FU via Bcl-2 and
Bcl-XL downregulation, and P53 activation. However, the authors performed their experimentation
using the hepatocellular carcinoma cell line BEL-7402/5-FU and proper validation using HB models
would be needed [45]. The mitochondrial uncoupling protein 2 (UCP2) has been identified as a
target of miR-214 in the hepatoblastoma cell line HuH6. Of importance, UCP2 overexpression
mediates resistance to gemcitabine in HCC patients. Moreover, ectopic miR-214 expression markedly
decreased HuH6 cell viability [46]. These results are in concordance with previous observations
indicating lower miR-214 levels in HB samples than in non-tumor tissues [47], highlighting the
potential therapeutic value.
Table 1. MicroRNAs with potential therapeutic value in Hepatoblastoma.
MicroRNA Role Therapeutic Impact References
miR-100/let-7a-2/
miR-125b-1 cluster Tumor supressor
In vivo cooperation. OE of the first cluster
concomitant with inhibition of the second one
blocked tumor formation
Cairo et al., 2010 [24]
miR-371 cluster Oncogenic
miR-122 Tumor supressor Sensitizes to 5-FU via Bcl-2 and Bcl-XL DR andP53 activation Yin et al., 2011 [45]
miR-214 Tumor supressor Sensitizes to gemcitabine via UCP2 targeting Yu et al., 2016 [46]
miR-624-5p Tumor supressor Targets β-catenin and impairs tumor growthin vivo Indersie et al., 2017 [26]
miR-4510 Tumor supressor Decreases proliferation and induces apoptosisin vitro through Wnt/β-catenin inhibition Cartier et al., 2017 [25]
miR-34a-5p Tumor supressor Reduces tumor growth andmicrovascular density Dong et al., 2016 [38]
miR-125b Tumor supressor Decreases cell growth, migration and invasion Pei et al., 2016 [31]
miR-492 Oncogenic
Targets CD44 and enhances
anchorage-independent growth, migration
and invasion
von Frowein et al.,
2018 [33]
miR-378a Tumor supressor Sensitizes to sorafenib and inhibits cellproliferation and invasion Fu et al., 2018 [48]
miR-26a-5p Tumor supressor Inhibits proliferation and colony formation Zhang et al., 2018 [37]
miR-1250-3p Tumor supressor Decreases cell growth and invasion Liu et al., 2018 [49]
OE, Overexpression; DR, downregulation.
As the Wnt/β-catenin signaling is a main therapeutic target in HB, several studies have explored
the role of miRs in this pathway. Thus, Indersie and colleagues identified 4 miRs (let-7i-3p, miR-449-3p,
miR-624-5p and miR-885-5p) decreased in HB samples compared to normal liver controls that
regulate β-catenin expression and inhibit both cell proliferation and Wnt/β-catenin activity in vitro.
Moreover, miR-624-5p impaired tumor growth in vivo and directly targeted β-catenin by its 3′UTR
binding [26]. Another study showed that transfection with the miR-4510 precursor resulted in
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decreased cell proliferation and induced apoptosis of HuH6 cells probably through the inhibition of
the Wnt/β-catenin pathway, indicating the potential usefulness of this miR as a therapeutic target [25].
Furthermore, several works have demonstrated that miR-34a, miR-125b, miR-492, miR-378a,
and miR-26a-5p could represent novel valuable molecular targets in HB. In fact, transfection with a
precursor of the miR-34a-5p has been shown to markedly reduce HB tumor growth in vivo together
with lower microvascular density and number of proliferating tumor cells, which further highlights the
role of this miR in tumor angiogenesis [38]. The GATA4/miR-125b/DKK3 axis has been proposed as a
potential therapeutic target in this disease. Specifically, inhibition of miR-125b promoted cell growth,
migration, and invasion of hepatoma HuH6 cells [31]. The oncogenic miR-492 has been recently
proposed as a potential therapeutic target based on its ability to regulate the metastatic progression of
HB via CD44 regulation [33]. It has been reported that miR-378a inhibits proliferation and invasion
abilities as well as enhances the sensitivity of HB cells to sorafenib-based chemotherapy through the
negative regulation of its targets VEGFR, PDGFRβ, and c-Raf [48]. In addition, the tumor suppressor
miR-26a-5p inhibits cell proliferation and colony formation of HepG2 and HuH6 cells, suggesting its
potential usefulness as a novel molecular target in HB [37].
Interestingly, the role of circular RNAs (circRNAs) as potential miR regulators has been
investigated in a study that performed circRNA microarrays in HB samples and normal liver controls.
The authors found that circ_0015756 acts as an miR-1250-3p sponge, inhibiting its tumor suppressor
function and affecting cell viability and invasion of HuH6 cells [49].
4. MicroRNA Expression Patterns and Their Potential Clinical Impact as Novel Biomarkers
in Hepatoblastoma
Apart from being essential for all the tumor-related processes mentioned above, miRs expression
profiles have progressively emerged as useful biomarkers in human cancers. In fact, miR expression
profiling in HB has been analyzed in several studies [24,32,44,50]. The first study involving the analysis
of miR expression in HB patients was performed by Magrelli and colleagues in 2009. MiR expression
was assayed by microarray and quantitative reverse transcription polymerase chain reaction in
samples from nine HB cases. They described a set of 13 miRs which were able to discriminate
tumor from non-tumor tissues and 5 miRs differentially expressed in HB compared to hepatocellular
carcinoma (HCC) (four significantly upregulated: miR-214, miR-199a, miR-150 and miR-125a, and
one downregulated: miR-148a) [50]. Of interest, miR-125a has been reported to target Tafazzin (TAZ),
thereby impairing retinoblastoma proliferation, and it would be very interesting to analyze its potential
role in regulating the Hippo pathway in HB [51]. Next, distinct miR profiles were observed between
mild and aggressive HB subtypes with 20 miRs differentially expressed (5 miRs upregulated and
15 downregulated in the aggressive subtype in comparison with the mild subtype). Of importance,
a four-miR signature (miR-100, let-7a, miR-371, and miR-373) efficiently discriminated aggressive HB
in a training set of 19 HBs and a test set of 46 HBs. In fact, this miR signature was associated with
invasive, poorly differentiated, and metastatic HB tumors [24].
Overexpression of the oncogenic transcription factor PLAG1 is a frequent alteration in HB [52].
MiR-492 has been proposed as a potential biomarker in metastatic HB (Table 2). This miR was identified
to be located within the HB marker gene keratin 19 (KRT19), a marker for hepatic progenitors and cancer
stem cells, previously related to the metastatic progression of HCC [53,54]. PLAG1 might co-regulate
the expression of KRT19 and the miR-492 release. Significantly higher levels of co-expressed KRT19
and miR-492 were found in metastatic HB tumor samples, suggesting their role in the progression
of this disease [32]. Recently, the same group has reported that miR-492 overexpression correlates
with metastatic disease and high-risk tumors and determines reduced event-free survival in a cohort
of 44 HB patients [33]. All the reported miRNAs with clinical value as biomarkers in HB have been
included in Table 2.
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Table 2. MicroRNAs as prognostic markers in Hepatoblastoma.
MicroRNA Expression Clinical Significance References
miR-492 High Metastatic disease [30]
miR-21 High
Independent markers of increased survival [41]
miR-222 and miR-224 Low
Combined miR-34a/b/c Low Independent unfavourable prognostic factor [53]
Exosomal miR-21 High Independent predictor of larger EFS 1 [52]
Exosomal miR-34a/b/c Low Independent unfavourable prognostic factor [54]
miR-492 High Correlation with aggressive tumors and reduced EFS 1 [31]
miR-17 Low Worse prognosis [51]
1 Event-free Survival.
Another study analyzed miR expression in the main HB epithelial subtypes, revealing different
miR expression patterns in fetal and embryonal HB. The authors observed higher levels of miR-18a in
embryonal compared to fetal samples, but histological classification did not correlate with survival.
In HB embryonal samples, lower miR-122 levels were observed compared to liver normal tissue,
whereas higher miR-221 and lower miR-17-5p, miR-195, miR-210, and miR-214 were detected in HB
fetal samples. Of note, low miR-222 and miR-224, and high miR-21 independently predicted larger
overall survival in that HB cohort. However, the small number of HB samples included (n = 23) and
the fact that only 14 miRs were measured are important limitations of this study [47]. Conversely,
if we analyze the miR expression patterns during liver development, we surprisingly observed an
inverse correlation regarding miR expressions in embryonic and fetal HB. Thus, miR-18a is highly
expressed in adult compared to embryonic liver, and miR-122 is overexpressed in embryonic and
fetal compared to the adult liver [55]. Of note, a recent study in a cohort of 22 HB patients showed
that expression levels of miR-17 were significantly lower in tumor samples and correlate with worse
prognosis. In this work, miR-19b was found overexpressed in the embryonal subtype compared to
fetal subtype [56]. In concordance with these results, both exosomal and plasma in miR-21 were found
significantly higher in a cohort of 32 HB samples compared with a control group. Vascular invasion,
PRETEXT staging system, tumor metastases, and exosomal miR-21 were independent risk factors that
could affect the event-free survival of HB patients. Moreover, it was found that exosomal miR-21 was
significantly more accurate as compared with the alpha-fetoprotein (AFP) levels in diagnosing HB [57].
Interestingly, a larger study including 76 HB patients identified that combined low miR-34a/b/c
expression independently predicts poor prognosis [58]. The same group confirmed these results
using an exosomal miR-34a/b/c panel in an independent cohort of 89 HB patients, observing that
the prognostic value of a panel of serum exosomal miRNAs including miR-34a/b/c was superior to
other risk factors such as AFP. Although this miRNA panel also showed diagnostic value, in this case,
there were no differences compared to AFP levels [59]. Moreover, miR-4510 was found downregulated
in HB tumors compared to adjacent normal liver samples, probably based on its tumor suppressor
role as an inhibitor of the Wnt/β-Catenin pathway [25]. Finally, a study involving the comparison
between three independent platforms (next-generation sequencing, microarray, and NanoString) in
12 formalin fixed paraffin embedded (FFPE) samples from HB patients identified an alternative pattern
in a poorly-differentiated HB with an aggressive phenotype [60,61].
5. Conclusions
New biological studies involving miRs could serve to identify novel effective biomarkers with
prognostic value that would be helpful for risk stratification as well as provide alternative therapeutic
strategies for the treatment of HB, especially in those patients with advanced tumors or metastatic
disease. Thus, the identification of promising candidates for miR replacement therapy may represent a
very interesting therapeutic solution. However, most of the studies involving miRNA in HB have been
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performed using a relatively small number of samples, and in some cases, they have included only a
group of candidate miRNAs rather than a global analysis.
Therefore, further validation using large patient cohorts and preclinical models such as HB
patient-derived xenografts is required and would highlight which of these progressive findings
involving miRs will be extended to future clinical studies.
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